Progenics Pharmaceuticals, Inc. (PGNX)


Stock Price Forecast

June 19, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Progenics Pharmaceuticals, Inc. chart...

About the Company

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Sector

Health Technology

Industry

Biotechnology

Employees

105

CEO

David W. Mims

Exchange

NASDAQ

Website

http://www.progenics.com

$37M

Total Revenue

105

Employees

$353M

Market Capitalization

-5.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PGNX News

New Suit - Patent

24d ago, source: Law

Counsel have not yet appeared for the defendant. The case is 1:24-cv-10437, Progenics Pharmaceuticals, Inc. v.

Asha Das's Net Worth

1mon ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Tocagen Inc, and PROGENICS PHARMACEUTICALS INC. Attention insiders: Dive deeper into market movements and stay ahead of ...

Alnylam Pharmaceuticals

1d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Amneal Pharmaceuticals Inc.

4d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Ionis Pharmaceuticals Inc IONS

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CYCC Cyclacel Pharmaceuticals, Inc.

3d ago, source: Seeking Alpha

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s lead product includes ...

Vertex Pharmaceuticals Inc VRTX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SNOA Sonoma Pharmaceuticals, Inc.

3d ago, source: Seeking Alpha

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the ...

Oramed Pharmaceuticals Inc.

1mon ago, source: CNN

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions ...

Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know

28d ago, source: Yahoo Finance

Investors might want to bet on Apellis Pharmaceuticals, Inc. (APLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

1mon ago, source: Yahoo Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) future prospects. Tarsus Pharmaceuticals, Inc., a ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...